Skip to main content

Catalyst Calendar

Scope

Wed, Aug 12, 2026

1 updates
CGEM
7:30 PM

Zipalertinib Plus Chemotherapy Meets Primary Endpoint of Progression-Free Survival in Planned Interim Analysis of Phase 3 REZILIENT3 Trial in First-Line EGFR Exon 20 Insertion Mutation Non-Small Cell Lung Cancer

PRINCETON, New Jersey, TOKYO, Japan, CAMBRIDGE, Mass., August 12, 2026 — Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Cullinan Therapeutics, Inc. (Nasdaq: CGEM) today announced that the REZILIENT3 trial, a global Phase 3 clinical trial evaluating the combination of zipalertinib and

Trial Results • Phase 3REZILIENT3 interim analysis results Wed, Aug 12, 2026cullinantherapeutics.com

Thu, Aug 6, 2026

1 updates

Tue, Jul 28, 2026

1 updates

Wed, Jun 10, 2026

1 updates
CGEM
7:30 AM

Cullinan Therapeutics Shares New Clinical Data Across Its Portfolio of T Cell Engager Programs Targeting CD19 and BCMA in Autoimmune Diseases

CLN-978 (CD19 TCE) EULAR data demonstrated potential for immune reset, including remissions, in both systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) CLN-978 data from the first RA multi-dose regimen cohort demonstrated robust efficacy, including clinical remission in a

Presentation / Abstract • Phase 1EULAR 2026 Congress presentation Wed, Jun 10, 2026cullinantherapeutics.com

Sat, Jun 6, 2026

1 updates
CGEM
5:15 AM

Cullinan Therapeutics Presents Initial Clinical Data for CLN-978, a CD19xCD3 T Cell Engager, at the EULAR 2026 Congress

Clinical benefit, including remissions, demonstrated in both systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) patients following a single target dose of CLN-978 Deep, dose-dependent B cell depletion observed in peripheral blood and tissue Favorable safety profile with single target

Presentation / Abstract • Phase 1Poster presentation Sat, Jun 6, 2026, 10:15 AM BSTcullinantherapeutics.com

Tue, May 26, 2026

1 updates
CGEM
7:00 AM

Cullinan Therapeutics to Host Immunology Day to Showcase Promising Initial Clinical Data in Autoimmune Diseases for CLN-978, a CD19 T Cell Engager, and Velinotamig, a BCMA T Cell Engager

New and updated clinical data to be presented from over 30 patients across systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) studies Initial data from the first multi-dose cohort of RA study to be presented Initial data from the first multi-dose cohort of velinotamig study also to

Results CallResults call Wed, Jun 10, 2026, 8:30 AM ETcullinantherapeutics.com

Tue, May 19, 2026

1 updates

Mon, May 18, 2026

1 updates
CGEM
5:00 PM

Cullinan Therapeutics to Present Initial Clinical Data for CLN-978 in Treatment-Refractory Rheumatoid Arthritis and Systemic Lupus Erythematosus at EULAR 2026 Congress

CAMBRIDGE, Mass., May 18, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, high-impact therapies in autoimmune diseases and cancer, today announced that initial clinical data from two

Presentation / Abstract • Phase 1Poster presentation Sat, Jun 6, 2026, 10:15 AM BSTcullinantherapeutics.com